US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Weight Loss Drugs

1,262.57

-90.6577-6.70%

Number of Gainers:1

Number of Losers:6

Number of Flat:- -

PE:- -

High:1,362.19

Open:1,356.11

Low:1,242.41

Close:1,353.23

Loading ...

BUZZ-Pfizer beats quarterly profit beat, maintains 2025 forecast; shares rise

Why Viking Therapeutics Stock Popped Again Today

Pfizer Shares Reverse Course, Last up 4.3%

THOMSON REUTERS

Pfizer Shares Rise After Q1 Profit Beats, Reaffirms 2025 Outlook

Hims & Hers Soars 40% as Novo Nordisk Expands Wegovy Access via Telehealth

Pfizer Reports Mixed First Quarter, Affirms Full-Year Outlook

Pfizer CEO Bourla Says Co "Not Going to Be a Strong Top Line Growth Story for Next Three Years, Given Loes, We Expect to Become EPS Growth Story"

THOMSON REUTERS

Pfizer CEO Says Co Has "Ample Room IF There Is a Need to Transfer Production" of Medicines to United States - Conf Call

THOMSON REUTERS

Pfizer Eyes Acquisitions After Obesity Drug Setback

Hims & Hers Skyrockets 33% After Tapping the $499 Weight-Loss Goldmine

LifeMD Expands Access to Weight-Loss Drug Wegovy; Shares Surge

MT Newswires Live

Pfizer Shares Fall 1.8% After Q1 Revenue Miss

THOMSON REUTERS

Hims & Hers' stock rockets after teaming up with its rival Wegovy maker

Hims & Hers to Sell Novo Nordisk's Wegovy in U.S., Shares Soar -- Update

Hims & Hers Rallies After Novo Nordisk Deal on Wegovy

BRIEF-FDA Heparin Sodium, Injection, 5000 [Usp'u]/1 Ml To Be Discontinued Due To Business Decision - Website

Jim Cramer on Eli Lilly and Company (LLY): “Riding the wave of GLP-1 success” – Ready to Rebound After a Rare Miss

FDA: Heparin Sodium, Injection, 5000 [Usp'u]/1 Ml to Be Discontinued Due to Business Decision - Website

THOMSON REUTERS

Is Eli Lilly and Company (LLY) the Best Long-Term Dividend Stock to Buy According to Billionaires?

BRIEF-Pfizer - Expects About $1.6 Bln One-Time Costs To Achieve Additional Savings To Be Incurred Through 2027 - SEC Filing

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK4599/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4599","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4599\",,,,,undefined,":{"symbol":"BK4599","market":"US","secType":"PLATE","nameCN":"Weight Loss Drugs","latestPrice":1262.5677,"timestamp":1746128452813,"preClose":1353.2255,"halted":0,"volume":64442835,"delay":0,"changeRate":-0.066994,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":-90.657715,"latestTime":"05-01 15:40:52 EDT","open":1356.1058,"high":1362.19,"low":1242.4124,"amount":11097209154.915848,"amplitude":0.088513,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1746129600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":10.487449,"peRate":36.838608,"turnoverRate":0.006098,"increases":1,"decrements":6,"flats":0,"marketCap":1351129428800,"floatMarketCap":1265861887776},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4599\",,,,,undefined,":{"symbol":"BK4599","high":1362.19,"amplitude":0.088513,"preClose":1353.2255,"low":1242.4124,"pbRate":"10.487449","latestPrice":1262.5677,"volume":64442666,"delay":0,"open":1356.1058,"prevYearClose":1305.0607,"prevWeekClose":1313.4298,"prevMonthClose":1353.2255,"prevQuarterClose":1314.3724,"fiveDayClose":1291.0822,"twentyDayClose":1296.1409,"sixtyDayClose":1354.5123,"secType":"PLATE","market":"US","turnoverRate":0.006098,"peRate":36.838608,"marketCap":1351129428800,"floatMarketCap":1265861887776,"timestamp":1746128452012,"nameCN":"Weight Loss Drugs"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4599\",,,,undefined,":{"bkCode":"BK4599","up":1,"down":6,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4599\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2531766423","title":"BUZZ-Pfizer beats quarterly profit beat, maintains 2025 forecast; shares rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2531766423","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531766423?lang=en_us&edition=fundamental","pubTime":"2025-04-30 00:41","pubTimestamp":1745944907,"startTime":"0","endTime":"0","summary":"BUZZ-Pfizer beats quarterly profit beat, maintains 2025 forecast; shares riseUpdates** Pfizer's PFE.N shares rise 4.4% to $24.06. ** Stock set for its biggest single-day pct. jump in nearly 4 months, if gains hold. ** PFE posts Q1 adj. EPS of $0.92, beating analysts' estimates of $0.67, according to data compiled by LSEG** PFE's Q1 revenue misses estimates due to declining sales of its Paxlovid COVID-19 treatment, but co still sticks by FY revenue forecast of $61 billion-$64 billion** Co says it would generate $1.7 billion more in savings from cost-cutting to its manufacturing and research operations** Including session's moves, PFE has fallen about 10% YTD ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nL4N3R721V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0321505439.SGD","IE00B19Z3581.USD","IE00BBT3K403.USD","IE000M9KFDE8.USD","LU0058720904.USD","LU1023059063.AUD","IE00B19Z3B42.SGD","SG9999013999.USD","SG9999003800.SGD","LU1894683264.USD","BK4550","LU0289739699.SGD","LU0321505868.SGD","LU0170899867.USD","SG9999002232.USD","BK4581","BK4007","LU0225284248.USD","PFE","LU0234572021.USD","BK4592","BK4534","BK4585","LU0225771236.USD","LU0306807586.USD","LU1883839398.USD","IE0002270589.USD","LU0306806265.USD","LU0456855351.SGD","SGXZ57979304.SGD","SG9999001176.USD","LU1057294990.SGD","SG9999002224.SGD","SG9999011175.SGD","IE00BLSP4452.SGD","SG9999001176.SGD","BK4599","LU0122379950.USD","IE00BLSP4239.USD","LU0985481810.HKD","BK4568","LU0868494617.USD","LU1066053197.SGD","LU1894683348.USD","LU1066051498.USD","BK4533","BK4588"],"gpt_icon":1},{"id":"2531765748","title":"Why Viking Therapeutics Stock Popped Again Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2531765748","media":"Motley Fool","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531765748?lang=en_us&edition=fundamental","pubTime":"2025-04-30 00:24","pubTimestamp":1745943840,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald thinks the GLP-1 diet drug VK2735 will be a \"multi-blockbuster\" for Viking stock.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/04/29/why-viking-therapeutics-stock-popped-again-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["BK4139","BK4599","VKTX","BK4585","BK4588"],"gpt_icon":0},{"id":"2531925763","title":"Pfizer Shares Reverse Course, Last up 4.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2531925763","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531925763?lang=en_us&edition=fundamental","pubTime":"2025-04-30 00:13","pubTimestamp":1745943200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nL4N3R721T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SG9999013999.USD","LU1894683264.USD","LU0225771236.USD","LU0321505868.SGD","IE0002270589.USD","BK4581","PFE","LU0058720904.USD","IE000M9KFDE8.USD","IE00BLSP4452.SGD","BK4592","SG9999002224.SGD","SG9999002232.USD","LU0289739699.SGD","LU1023059063.AUD","LU1883839398.USD","IE00BLSP4239.USD","BK4568","LU0306806265.USD","LU1066051498.USD","SG9999003800.SGD","SG9999001176.SGD","LU0225284248.USD","LU0122379950.USD","BK4550","LU1057294990.SGD","LU0868494617.USD","BK4534","IE00B19Z3581.USD","LU1894683348.USD","LU0456855351.SGD","IE00B19Z3B42.SGD","BK4585","LU0321505439.SGD","LU0234572021.USD","SG9999011175.SGD","BK4533","BK4007","BK4599","BK4588","LU0306807586.USD","IE00BBT3K403.USD","SG9999001176.USD","LU1066053197.SGD","LU0985481810.HKD","LU0170899867.USD","SGXZ57979304.SGD"],"gpt_icon":0},{"id":"2531762025","title":"Pfizer Shares Rise After Q1 Profit Beats, Reaffirms 2025 Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2531762025","media":"GuruFocus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531762025?lang=en_us&edition=fundamental","pubTime":"2025-04-30 00:01","pubTimestamp":1745942472,"startTime":"0","endTime":"0","summary":"Based on the one year price targets offered by 19 analysts, the average target price for Pfizer is $28.71 with a high estimate of $41.43 and a low estimate of $22.00. The average target implies an upside of 21.18% from the current price of $23.69.Based on GuruFocus estimates, the estimated GF Value for Pfizer Inc in one year is $28.58, suggesting an upside of 20.64% from the current price of $23.69.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gurufocus.com/news/2812354/pfizer-shares-rise-after-q1-profit-beats-reaffirms-2025-outlook","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gurufocus_highlight","symbols":["LU0321505439.SGD","IE00B19Z3581.USD","IE00BBT3K403.USD","IE000M9KFDE8.USD","LU0058720904.USD","LU1023059063.AUD","IE00B19Z3B42.SGD","SG9999013999.USD","SG9999003800.SGD","LU1894683264.USD","BK4550","LU0289739699.SGD","LU0321505868.SGD","LU0170899867.USD","SG9999002232.USD","BK4581","BK4007","LU0225284248.USD","PFE","LU0234572021.USD","BK4592","BK4534","BK4585","LU0225771236.USD","LU0306807586.USD","LU1883839398.USD","IE0002270589.USD","LU0306806265.USD","LU0456855351.SGD","SGXZ57979304.SGD","SG9999001176.USD","LU1057294990.SGD","SG9999002224.SGD","SG9999011175.SGD","IE00BLSP4452.SGD","SG9999001176.SGD","BK4599","LU0122379950.USD","IE00BLSP4239.USD","LU0985481810.HKD","BK4568","LU0868494617.USD","LU1066053197.SGD","LU1894683348.USD","LU1066051498.USD","BK4533","BK4588"],"gpt_icon":1},{"id":"2531761220","title":"Hims & Hers Soars 40% as Novo Nordisk Expands Wegovy Access via Telehealth","url":"https://stock-news.laohu8.com/highlight/detail?id=2531761220","media":"GuruFocus.com","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531761220?lang=en_us&edition=fundamental","pubTime":"2025-04-29 23:54","pubTimestamp":1745942055,"startTime":"0","endTime":"0","summary":"Hims & Hers Health  shares soared 40% in premarket trading Tuesday after Novo Nordisk  said it would begin offering its blockbuster weight-loss drug Wegovy through telehealth providers, including HIMS, Ro, and LifeMD.Novo Nordisk stock  climbed 3% following the announcement, which comes as the Danish drugmaker moves to solidify access to Wegovy amid rising demand and tighter restrictions on compounded alternatives.GuruFocus has detected 3 Warning Sign with HIMS.The new collaboration allows patients to receive Wegovy via direct-to-consumer channels like NovoCare, Novo Nordisk's online pharmacy, which integrates with the telehealth platforms. The drug will be offered at a discounted rate of $499 per month through NovoCare for patients without insurance.Hims & Hers will begin providing all Wegovy dose sizes this week, with added services such as 24/7 clinical care and nutritional support. The total monthly cost will start at $599.The shift comes as compounded semaglutide, cheaper, unappro","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/hims-hers-soars-40-novo-155415633.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","IE00BKVL7J92.USD","BK4585","LU0154236417.USD","BK4532","IE00BZ1G4Q59.USD","HIMS","NVO","BK4599","LU1093756325.SGD","LU1093756168.USD","BK4588","BK4196"],"gpt_icon":1},{"id":"2531752767","title":"Pfizer Reports Mixed First Quarter, Affirms Full-Year Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2531752767","media":"MT Newswires","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531752767?lang=en_us&edition=fundamental","pubTime":"2025-04-29 22:47","pubTimestamp":1745938030,"startTime":"0","endTime":"0","summary":"Pfizer's  first-quarter earnings unexpectedly increased year on year even as sales fell below Wall Street's estimates, while the pharmaceutical giant reiterated its full-year outlook.Adjusted per-share earnings rose to $0.92 from $0.82 a year earlier and surpassed the consensus on FactSet of $0.67. Revenue fell 8% to $13.72 billion, below analysts' $13.92 billion estimate.For 2025, the company continues to expect adjusted EPS guidance of $2.80 to $3 and revenue of $61 billion to $64 billion. Analysts are looking for non-GAAP EPS of $2.94 on revenue of $62.75 billion. In the previous year, adjusted EPS surged 69% to $3.11, while sales rose 7% to $63.63 billion.\"In addition, we have identified additional opportunities to drive improvements in productivity and operational efficiency in our  organization through enhanced digital enablement and automation,\" according to the CFO. \"We expect approximately $500 million in savings associated with these efforts to be realized by the end of 2026 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pfizer-reports-mixed-first-quarter-144710844.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0868494617.USD","LU0225771236.USD","BK4585","LU0234572021.USD","LU0321505868.SGD","BK4568","LU1894683264.USD","LU0985481810.HKD","LU0170899867.USD","IE00BLSP4452.SGD","IE00BBT3K403.USD","LU0058720904.USD","BK4007","BK4533","LU0306806265.USD","LU1023059063.AUD","SG9999011175.SGD","SGXZ57979304.SGD","IE000M9KFDE8.USD","LU1066053197.SGD","LU0122379950.USD","IE00BLSP4239.USD","IE00B19Z3B42.SGD","SG9999002224.SGD","IE0002270589.USD","SG9999001176.USD","LU0289739699.SGD","LU1883839398.USD","SG9999003800.SGD","BK4599","IE00B19Z3581.USD","BK4550","BK4588","LU0456855351.SGD","PFE","BK4581","SG9999013999.USD","LU1066051498.USD","LU0321505439.SGD","LU1894683348.USD","BK4592","BK4534","LU0306807586.USD","LU1057294990.SGD","SG9999002232.USD","LU0225284248.USD","SG9999001176.SGD"],"gpt_icon":1},{"id":"2531751132","title":"Pfizer CEO Bourla Says Co \"Not Going to Be a Strong Top Line Growth Story for Next Three Years, Given Loes, We Expect to Become EPS Growth Story\"","url":"https://stock-news.laohu8.com/highlight/detail?id=2531751132","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531751132?lang=en_us&edition=fundamental","pubTime":"2025-04-29 22:42","pubTimestamp":1745937769,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nFWN3R726B:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00BLSP4239.USD","IE00B19Z3581.USD","SG9999001176.SGD","LU1066053197.SGD","BK4534","LU1066051498.USD","SG9999001176.USD","LU0122379950.USD","BK4581","LU1894683348.USD","LU1894683264.USD","LU0321505868.SGD","BK4592","IE00BBT3K403.USD","BK4550","SG9999002224.SGD","IE00B19Z3B42.SGD","BK4599","LU0306806265.USD","SG9999002232.USD","BK4585","SG9999013999.USD","LU0225284248.USD","LU0289739699.SGD","LU1057294990.SGD","SG9999003800.SGD","SG9999011175.SGD","BK4588","LU1023059063.AUD","LU0306807586.USD","LU0456855351.SGD","BK4533","IE00BLSP4452.SGD","LU0170899867.USD","PFE","LU0321505439.SGD","LU0234572021.USD","BK4007","LU0058720904.USD","LU0868494617.USD","LU0985481810.HKD","IE000M9KFDE8.USD","LU1883839398.USD","LU0225771236.USD","IE0002270589.USD","SGXZ57979304.SGD","BK4568"],"gpt_icon":0},{"id":"2531594047","title":"Pfizer CEO Says Co Has \"Ample Room IF There Is a Need to Transfer Production\" of Medicines to United States - Conf Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2531594047","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531594047?lang=en_us&edition=fundamental","pubTime":"2025-04-29 22:42","pubTimestamp":1745937769,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nFWN3R726B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0289739699.SGD","LU0456855351.SGD","BK4007","LU0321505868.SGD","BK4599","LU0225771236.USD","LU1894683264.USD","LU1066053197.SGD","SG9999003800.SGD","LU0306806265.USD","BK4592","LU0306807586.USD","LU0985481810.HKD","LU0122379950.USD","LU0234572021.USD","BK4585","SG9999011175.SGD","LU0868494617.USD","BK4588","SG9999013999.USD","LU1883839398.USD","BK4534","IE00BLSP4452.SGD","LU0170899867.USD","LU0225284248.USD","IE00B19Z3B42.SGD","SG9999002232.USD","IE00B19Z3581.USD","IE00BBT3K403.USD","LU1057294990.SGD","LU0058720904.USD","BK4581","SG9999001176.SGD","LU0321505439.SGD","SG9999002224.SGD","BK4568","IE0002270589.USD","LU1066051498.USD","BK4533","LU1894683348.USD","SGXZ57979304.SGD","SG9999001176.USD","BK4550","PFE","IE00BLSP4239.USD","IE000M9KFDE8.USD","LU1023059063.AUD"],"gpt_icon":0},{"id":"2531751895","title":"Pfizer Eyes Acquisitions After Obesity Drug Setback","url":"https://stock-news.laohu8.com/highlight/detail?id=2531751895","media":"GuruFocus.com","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531751895?lang=en_us&edition=fundamental","pubTime":"2025-04-29 22:32","pubTimestamp":1745937141,"startTime":"0","endTime":"0","summary":"Pfizer  is overhauling its cardiometabolic pipeline and weighing acquisitions after an oral weight-loss candidate stumbled, even as its Q1 results delivered a mixed bag of beats and misses.GuruFocus has detected 6 Warning Signs with PFE.The New Yorkbased drugmaker reported $13.7 billion in first-quarter revenue, roughly $400 million shy of analysts' $14.09 billion consensus, but topped bottom-line forecasts and confirmed its 2025 earnings outlook.Revenue slid about 8% year-over-year, driven largely by a steep drop in Paxlovid sales to $491 million versus a $902 million forecast. That decline was only partly offset by Comirnaty, Pfizer's COVID vaccine co-developed with BioNTech, which generated $565 million and outpaced the $325.5 million estimate.He added that Pfizer would build our cardiometabolic pipeline, including in obesity, by advancing internal programs such as our GIPR antagonist and pursuing external opportunities that could include partnerships or acquisitions. That strategic","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pfizer-eyes-acquisitions-obesity-drug-143221205.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SG9999003800.SGD","SG9999001176.SGD","LU0225771236.USD","LU0058720904.USD","LU1023059063.AUD","BK4533","LU0985481810.HKD","PFE","SG9999002232.USD","SG9999002224.SGD","IE00B19Z3B42.SGD","LU0122379950.USD","BK4007","BK4550","BK4588","LU0321505868.SGD","LU0306807586.USD","IE00BBT3K403.USD","LU0321505439.SGD","LU0234572021.USD","SG9999001176.USD","BK4585","BK4592","BK4568","LU1066053197.SGD","LU1066051498.USD","IE00BLSP4452.SGD","IE00BLSP4239.USD","SGXZ57979304.SGD","SG9999013999.USD","LU0868494617.USD","LU1883839398.USD","LU1894683264.USD","BK4534","IE000M9KFDE8.USD","BK4581","LU0456855351.SGD","BK4599","SG9999011175.SGD","LU0170899867.USD","LU0289739699.SGD","IE00B19Z3581.USD","LU0225284248.USD","LU0306806265.USD","LU1057294990.SGD","IE0002270589.USD","LU1894683348.USD"],"gpt_icon":1},{"id":"2531752750","title":"Hims & Hers Skyrockets 33% After Tapping the $499 Weight-Loss Goldmine","url":"https://stock-news.laohu8.com/highlight/detail?id=2531752750","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531752750?lang=en_us&edition=fundamental","pubTime":"2025-04-29 22:27","pubTimestamp":1745936829,"startTime":"0","endTime":"0","summary":"Hims & Hers Health  shares exploded 33% at 8:10 am in the premarket trading today after announcing a major expansion of its telehealth weight-loss offerings through a new direct partnership with Novo Nordisk's  NovoCare Pharmacy. Patients can now access authentic, FDA-approved Wegovy through Hims & Hers, LifeMD, and Ro, using a streamlined self-pay model priced at $499 per month. With supply fully restored, the move positions Hims & Hers to capitalize on soaring demand as weight-loss treatments reshape the healthcare landscape.Wegovy, first approved in 2021, has rapidly become a game-changer for chronic weight management, offering the first weekly GLP-1 therapy for obesity. Its value grew even stronger in 2024 when the FDA expanded its label to cover cardiovascular risk reduction, helping it reach nearly 1.5 million patients across the U.S. By tapping into Novo Nordisk's direct distribution model, Hims & Hers is not only expanding its footprint in one of the fastest-growing markets but","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/hims-hers-skyrockets-33-tapping-142709459.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4196","IE00BZ1G4Q59.USD","HIMS","BK4532","BK4599","IE00BKVL7J92.USD","LU1093756168.USD","BK4585","BK4007","BK4588","LU1093756325.SGD","LU0154236417.USD","NVO"],"gpt_icon":1},{"id":"2531730669","title":"LifeMD Expands Access to Weight-Loss Drug Wegovy; Shares Surge","url":"https://stock-news.laohu8.com/highlight/detail?id=2531730669","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531730669?lang=en_us&edition=fundamental","pubTime":"2025-04-29 21:38","pubTimestamp":1745933936,"startTime":"0","endTime":"0","summary":"LifeMD  said Tuesday that it plans to offer \"broad, affordable, and streamlined\" access to Novo Nordisk's  weight-loss drug Wegovy.The company said all doses of Wegovy are available in a pen device to eligible LifeMD patients who are uninsured or do not have weight-loss medication coverage through their insurance provider.Shares of LifeMD surged 22% in early trading Tuesday.Price: 7.47, Change: +1.37, Percent Change: +22.46","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4183","NVO.AU","BK7104","LFMD","IE00BZ1G4Q59.USD","BK4167","LU1093756168.USD","BK4532","BK4599","IE00BKVL7J92.USD","BK4585","BK4007","BK4588","LU1093756325.SGD","LU0154236417.USD"],"gpt_icon":1},{"id":"2531342737","title":"Pfizer Shares Fall 1.8% After Q1 Revenue Miss","url":"https://stock-news.laohu8.com/highlight/detail?id=2531342737","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531342737?lang=en_us&edition=fundamental","pubTime":"2025-04-29 21:32","pubTimestamp":1745933557,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nFWN3R71QW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4592","IE0002270589.USD","LU0868494617.USD","IE00B19Z3B42.SGD","LU1066053197.SGD","LU1894683264.USD","LU0225771236.USD","LU1057294990.SGD","IE00BLSP4239.USD","BK4585","SG9999001176.SGD","BK4550","BK4581","LU0985481810.HKD","LU0306807586.USD","PFE","SG9999002232.USD","LU0225284248.USD","LU0058720904.USD","BK4588","LU0289739699.SGD","LU0170899867.USD","SG9999001176.USD","LU1023059063.AUD","BK4568","SG9999011175.SGD","BK4533","BK4534","IE00BBT3K403.USD","IE00B19Z3581.USD","LU0321505439.SGD","LU0321505868.SGD","BK4599","BK4007","LU0234572021.USD","LU1066051498.USD","SG9999003800.SGD","SG9999002224.SGD","IE00BLSP4452.SGD","LU0306806265.USD","SG9999013999.USD","LU0456855351.SGD","LU1883839398.USD","SGXZ57979304.SGD","LU1894683348.USD","LU0122379950.USD","IE000M9KFDE8.USD"],"gpt_icon":0},{"id":"2531343177","title":"Hims & Hers' stock rockets after teaming up with its rival Wegovy maker","url":"https://stock-news.laohu8.com/highlight/detail?id=2531343177","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531343177?lang=en_us&edition=fundamental","pubTime":"2025-04-29 21:13","pubTimestamp":1745932380,"startTime":"0","endTime":"0","summary":"Health and wellness company, which sells alternatives to weight-loss drugs like Wegovy, is now collaborating with the Wegovy maker. Shares of Hims & Hers Health Inc. were headed for their best day ever early Tuesday trading, after the health and wellness company basically teamed up with its competition, the maker of the weight-loss drug Wegovy.The San Francisco-based company said the plan was to make obesity care \"more accessible, more affordable and more connected\" for Americans.The stock  soared 34.9% in premarket trading. It's on track to best the current record for a one-day gain of 31%, set on Feb. 27, 2024.The company announced a long-term collaboration with Denmark-based Novo Nordisk A/S , which makes Wegovy and diabetes-treatment Ozempic, which are both approved by the Food and Drug Administration. Hims & Hers made its name by selling alternatives to Wegovy.Starting this week, Hims & Hers members may be prescribed Wegovy, starting at $599 per month through NovoCare Pharmacy.Him","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823416689.USD","LU2552382058.USD","BK4599","LU1868836591.USD","BK4581","LU1023059063.AUD","IE0002141913.USD","LU2471134879.HKD","SG9999014914.USD","LU1291159041.SGD","LU0079474960.USD","LU2237443549.SGD","LU0672654240.SGD","LU0106261372.USD","LU2361044865.SGD","LU0006306889.USD","LU2491049909.HKD","HIMS","LU0471298694.HKD","BK4585","LU0122379950.USD","LU1069344957.HKD","LU1804176565.USD","LU1720051108.HKD","IE0009355771.USD","LU2602419157.SGD","LU1232071149.USD","LU2361044949.HKD","LU1064131342.USD","LU1868837136.USD","IE00BJT1NW94.SGD","LU2063271972.USD","LU0097036916.USD","SG9999018857.SGD","LU0256863902.USD","LU1712237335.SGD","LU2324357040.USD","LU0320765059.SGD","SG9999017495.SGD","LU0943347566.SGD","SG9999001176.USD","LU1551013342.USD","LU1057294990.SGD","IE00BZ1G4Q59.USD","LU0114720955.EUR","LU2471134796.USD","LU0385154629.USD","LU0096364046.USD"],"gpt_icon":1},{"id":"2531734392","title":"Hims & Hers to Sell Novo Nordisk's Wegovy in U.S., Shares Soar -- Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2531734392","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531734392?lang=en_us&edition=fundamental","pubTime":"2025-04-29 21:12","pubTimestamp":1745932320,"startTime":"0","endTime":"0","summary":"Him & Hers Health and Novo Nordisk are collaborating to offer weight-loss treatment, including access to Wegovy along with other services to treat obesity.In a joint venture with Novo Nordisk, Hims & Hers will dispense all doses of Wegovy to Americans who buy eligible subscriptions, with plans starting at $599 a month. The offering will launch this week, the company said.Consumers will be able to access NovoCare Pharmacy through Him & Hers' platform as well as clinical support, nutrition guidance and a membership, the companies said in a statement Tuesday.Shares of the online pharmacy surged 34% to $38.25 premarket, but remain below February peaks. Novo Nordisk rose 4% to $65.10.\"Beyond this initial collaboration, the companies are developing a roadmap that combines Novo Nordisk's innovative medications with Hims & Hers ability to deliver access to quality care at scale, with the goal of improving long-term outcomes for more people living with chronic disease, and doing that more affor","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00BZ1G4Q59.USD","HIMS","LU1093756325.SGD","BK4196","BK4599","BK4532","BK4007","LU0154236417.USD","LU1093756168.USD","NVO","IE00BKVL7J92.USD","BK4585"],"gpt_icon":1},{"id":"2531445735","title":"Hims & Hers Rallies After Novo Nordisk Deal on Wegovy","url":"https://stock-news.laohu8.com/highlight/detail?id=2531445735","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531445735?lang=en_us&edition=fundamental","pubTime":"2025-04-29 20:39","pubTimestamp":1745930340,"startTime":"0","endTime":"0","summary":"Shares of online pharmacy Hims & Hers surged after it struck a deal with Danish obesity drug maker Novo Nordisk to sell its Wegovy drug in the U.S.In a joint venture with Novo Nordisk, Hims & Hers will dispense all doses of Wegovy to Americans who buy eligible subscriptions, with plans starting at $599 a month. The offering will launch this week, the company said.Shares of Hims & Hers soared 30% to $36.94 premarket, but remain below February peaks. Novo Nordisk rose 4% to $65.10.Glucagon-like Peptide receptor agonists, also known as GLP-1 drugs, are a blockbuster category of drugs that some industry analysts say will eventually be one of the top-selling kinds of pharmaceuticals ever. The GLP-1 products, including Novo Nordisk's Wegovy and Ozempic, have shown efficacy in the treatment of diabetes and in weight reduction, among other applications. Hims & Hers had previously sold compound-pharmacy versions of the drugs under a special arrangement due to shortages.Medical professionals hav","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ1G4Q59.USD","LU1093756325.SGD","BK4007","NVO","BK4588","BK4599","HIMS","LU1093756168.USD","BK4585","LU0154236417.USD","BK4532","IE00BKVL7J92.USD","BK4196"],"gpt_icon":1},{"id":"2531354597","title":"BRIEF-FDA Heparin Sodium, Injection, 5000 [Usp'u]/1 Ml To  Be Discontinued Due To Business Decision - Website","url":"https://stock-news.laohu8.com/highlight/detail?id=2531354597","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531354597?lang=en_us&edition=fundamental","pubTime":"2025-04-29 20:38","pubTimestamp":1745930329,"startTime":"0","endTime":"0","summary":"BRIEF-FDA Heparin Sodium, Injection, 5000 [Usp'u]/1 Ml To  Be Discontinued Due To Business Decision - WebsiteApril 29  - Pfizer Inc PFE.N:FDA: HEPARIN SODIUM, INJECTION, 5000 [USP'U]/1 ML TO  BE DISCONTINUED DUE TO BUSINESS DECISION - WEBSITESource text: [ID:]Further company coverage: PFE.N ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nFWN3R7234:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0306806265.USD","LU1023059063.AUD","LU0985481810.HKD","LU0289739699.SGD","LU1883839398.USD","SG9999003800.SGD","LU1057294990.SGD","BK4533","PFE","IE00BBT3K403.USD","IE00B19Z3581.USD","SG9999002232.USD","LU0122379950.USD","BK4581","BK4599","BK4568","SG9999002224.SGD","LU0456855351.SGD","LU0225771236.USD","LU0058720904.USD","LU0170899867.USD","IE00BLSP4452.SGD","SG9999001176.SGD","BK4550","BK4534","LU0321505439.SGD","LU0234572021.USD","LU0306807586.USD","SG9999013999.USD","LU1066053197.SGD","LU0868494617.USD","BK4007","LU1066051498.USD","IE00BLSP4239.USD","IE00B19Z3B42.SGD","LU1894683264.USD","BK4588","LU0321505868.SGD","IE0002270589.USD","LU1894683348.USD","SG9999011175.SGD","BK4592","IE000M9KFDE8.USD","SGXZ57979304.SGD","SG9999001176.USD","BK4585","LU0225284248.USD"],"gpt_icon":0},{"id":"2531365867","title":"Jim Cramer on Eli Lilly and Company (LLY): “Riding the wave of GLP-1 success” – Ready to Rebound After a Rare Miss","url":"https://stock-news.laohu8.com/highlight/detail?id=2531365867","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531365867?lang=en_us&edition=fundamental","pubTime":"2025-04-29 20:38","pubTimestamp":1745930301,"startTime":"0","endTime":"0","summary":"We recently published a list of Jim Cramer’s Game Plan for This Week: 16 Stocks in Focus. In this article, we are going to take a look at where Eli Lilly and Company  stands against other stocks that Jim Cramer discussed.On Friday, Mad Money host Jim Cramer took a close look at what he called one of the most important stretches of the earnings season, which came alongside major economic developments.“We made it. Yep, we got through another stretch without the White House upending the whole market, which therefore led to the second-best week of the year.”READ ALSOJim Cramer Put These 16 Stocks Under a MicroscopeandJim Cramer Recently Talked About These 15 Stocks. “Here’s the bottom line: This is a really consequential week ahead. We’re about to get into the weeds with tariffs, and we have to sort out what’s real and what’s just mandated by the president. Most important, we need to see some trade deals, please. With them, the market can absorb some earnings disappointments, but without t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/jim-cramer-eli-lilly-company-123821312.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","LLY","US2Y.BOND","US5Y.BOND","LU0096364046.USD","LU1061106388.HKD","LU1291159041.SGD","GB00BDT5M118.USD","LU0689472784.USD","LU2471134879.HKD","IE00B1BXHZ80.USD","US12M.BOND","US3Y.BOND","LU2552382215.SGD","LU2491049909.HKD","BK4599","LU1868837136.USD","LU0238689110.USD","LU1280957306.USD","SG9999017495.SGD","SGXZ99366536.SGD","US30Y.BOND","LU1868837300.USD","LU1804176565.USD","SG9999014914.USD","LU2491050071.SGD","BK4144","LU1720051108.HKD","GLP","IE00BJT1NW94.SGD","SG9999013999.USD","LU1064131342.USD","LU0882574055.USD","LU1551013342.USD","SG9999018865.SGD","US10Y.BOND","LU2106854487.HKD","US6M.BOND","IE00BK4W5M84.HKD","LU1868836757.USD","IE0004445239.USD","SG9999018857.SGD","US7Y.BOND","SGXZ81514606.USD","BK4516","IE0009355771.USD","SGXZ51526630.SGD","LU2361044865.SGD","LU1720051017.SGD","BK4588"],"gpt_icon":1},{"id":"2531359477","title":"FDA: Heparin Sodium, Injection, 5000 [Usp'u]/1 Ml to  Be Discontinued Due to Business Decision - Website","url":"https://stock-news.laohu8.com/highlight/detail?id=2531359477","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531359477?lang=en_us&edition=fundamental","pubTime":"2025-04-29 20:38","pubTimestamp":1745930289,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nFWN3R7234:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0456855351.SGD","BK4599","LU0225771236.USD","LU0985481810.HKD","SG9999003800.SGD","SG9999013999.USD","LU0234572021.USD","IE0002270589.USD","SG9999011175.SGD","BK4581","IE000M9KFDE8.USD","LU0170899867.USD","SG9999001176.SGD","BK4568","LU0321505439.SGD","LU0058720904.USD","LU1894683264.USD","LU0225284248.USD","BK4592","LU1894683348.USD","BK4550","IE00BLSP4452.SGD","IE00BLSP4239.USD","LU0306806265.USD","LU0289739699.SGD","IE00BBT3K403.USD","LU1023059063.AUD","BK4585","PFE","LU1066053197.SGD","LU1057294990.SGD","LU0306807586.USD","SGXZ57979304.SGD","LU0122379950.USD","LU1883839398.USD","BK4007","IE00B19Z3581.USD","BK4588","BK4534","LU0321505868.SGD","SG9999002232.USD","SG9999001176.USD","LU0868494617.USD","BK4533","LU1066051498.USD","SG9999002224.SGD","IE00B19Z3B42.SGD"],"gpt_icon":0},{"id":"2531173637","title":"Is Eli Lilly and Company (LLY) the Best Long-Term Dividend Stock to Buy According to Billionaires?","url":"https://stock-news.laohu8.com/highlight/detail?id=2531173637","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531173637?lang=en_us&edition=fundamental","pubTime":"2025-04-29 20:35","pubTimestamp":1745930152,"startTime":"0","endTime":"0","summary":"We recently published a list of the 10 Best Long-Term Dividend Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Eli Lilly and Company  stands against other best long-term dividend stocks.Dividend stocks are increasingly popular with both every day and billionaire investors. A CNBC report noted that for many, dividend stocks are always a solid choice, offering a steady income from corporate cash flow, which provides stability despite fluctuations in stock prices. With both the stock and bond markets experiencing significant volatility, these stocks are becoming even more attractive, serving as a balanced option between growth and yield for a broader range of investors.Dividend stocks are also a key component of many bil","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/eli-lilly-company-lly-best-123552841.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2491049909.HKD","LU1064131342.USD","SGXZ51526630.SGD","IE00BFTCPJ56.SGD","LU2491050071.SGD","LU2361044865.SGD","LU2552382215.SGD","LU1804176565.USD","LU0471298777.SGD","IE00BK4W5M84.HKD","LU1868837136.USD","SG9999017495.SGD","BK4516","LU1720051017.SGD","LU0094547139.USD","LU2471134879.HKD","LU1868837300.USD","BK4588","LU0689472784.USD","SG9999014914.USD","LU2106854487.HKD","BK4007","LU0106261372.USD","BK4599","LU0882574055.USD","LU1868836757.USD","LU2089984988.USD","LU0672654240.SGD","SGXZ99366536.SGD","SG9999001176.USD","LU1291159041.SGD","SGXZ81514606.USD","BK4585","GB00BDT5M118.USD","IE0004445239.USD","IE0009355771.USD","IE00B1BXHZ80.USD","LLY","LU1551013342.USD","SG9999018865.SGD","LU1023059063.AUD","LU1061106388.HKD","IE00BJT1NW94.SGD","LU0238689110.USD","LU0466842654.USD","LU0096364046.USD","SG9999013999.USD","SG9999018857.SGD","LU1720051108.HKD","LU1280957306.USD"],"gpt_icon":1},{"id":"2531833735","title":"BRIEF-Pfizer - Expects About $1.6 Bln One-Time Costs To Achieve Additional Savings To Be Incurred Through 2027 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2531833735","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531833735?lang=en_us&edition=fundamental","pubTime":"2025-04-29 20:29","pubTimestamp":1745929793,"startTime":"0","endTime":"0","summary":"BRIEF-Pfizer - Expects About $1.6 Bln One-Time Costs To Achieve Additional Savings To Be Incurred Through 2027 - SEC FilingApril 29  - Pfizer Inc PFE.N:PFIZER - EXPECTS ABOUT $1.6 BILLION ONE-TIME COSTS TO ACHIEVE ADDITIONAL SAVINGS TO BE INCURRED THROUGH 2027 - SEC FILINGPFIZER INC - EXPECTS $500 MILLION SAVINGS FROM RESEARCH AND DEVELOPMENT SIMPLIFICATION BY 2026 - SEC FILINGPFIZER INC - EXPECTS $600 MILLION ONE-TIME COSTS THROUGH 2026 FROM RESEARCH AND DEVELOPMENT SIMPLIFICATION  - SEC FILINGSource text: [ID:n0000078003-25-000111]Further company coverage: PFE.N ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nFWN3R714T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4550","LU0225284248.USD","LU0456855351.SGD","LU0306806265.USD","SG9999011175.SGD","IE00BBT3K403.USD","SG9999013999.USD","SGXZ57979304.SGD","SG9999003800.SGD","LU1883839398.USD","LU1894683264.USD","LU0289739699.SGD","LU0234572021.USD","BK4568","SG9999002232.USD","LU0306807586.USD","IE00BLSP4239.USD","BK4588","LU1023059063.AUD","PFE","BK4592","SG9999001176.SGD","LU0321505439.SGD","BK4585","LU1894683348.USD","LU0170899867.USD","BK4599","IE0002270589.USD","BK4533","LU0122379950.USD","IE00B19Z3B42.SGD","SG9999001176.USD","SG9999002224.SGD","LU1057294990.SGD","LU0058720904.USD","BK4534","LU0225771236.USD","IE000M9KFDE8.USD","IE00B19Z3581.USD","LU1066053197.SGD","BK4007","IE00BLSP4452.SGD","LU0868494617.USD","LU1066051498.USD","LU0985481810.HKD","LU0321505868.SGD","BK4581"],"gpt_icon":1}],"pageSize":20,"totalPage":10,"pageCount":3,"totalSize":200,"code":"91000000","status":"200"}]}}